Skeletal Muscle Stem Cells Guide

Overview

Myogenic progenitors differentiated from UCT-WJ-MSCs; capable of differentiating into myoblasts and myotubes with satellite cell-like properties for muscle regeneration

Related: Stem Cells Overview • Muscle Exosomes

FOR RESEARCH USE AND INTERNATIONAL USE ONLY

Specs	Details
Source	Derived from P2 UCT-WJ-MSCs via myogenic induction
Differentiation Protocol	5-azacytidine demethylation HGF IGF-1 myogenic medium
Cryopreservation	DMSO-free, glucose-based
Post-Thaw Viability	>98%
Storage	−80 °C long-term; −196 °C LN2 vapor phase for extended storage
Identity Markers	MyoD⁺, Myogenin⁺, Desmin⁺, Pax7⁺ (satellite cell marker), Myosin Heavy Chain⁺ (in mature myotubes).
Release Criteria	Spontaneous myotube formation confirmed in culture (multinucleated, Desmin⁺ myotubes); IGF-1 and HGF secretion confirmed by ELISA
Immunogenicity	HLA-DR⁻ (retained from UCT-WJ-MSC origin); immune-privileged for allogeneic delivery without immunosuppression
Passage Limit	≤P2 from UCT-WJ-MSC
Manufacturing	cGMP, animal-product-free

Clinical Overview

Skeletal muscle has significant but limited regenerative capacity mediated by resident satellite cells (muscle stem cells). In conditions of chronic muscle wasting, aging sarcopenia, severe trauma, or genetic myopathies (Duchenne, Becker), satellite cell depletion and fibrosis accumulation impair natural repair. Akira Skeletal Muscle Stem Cells derived from UCT-WJ-MSCs^[1] provide an exogenous source of highly proliferative myogenic progenitors that integrate into damaged muscle via satellite cell niche engagement. They fuse with damaged myofibers, form new multinucleated myotubes, release pro-myogenic growth factors (IGF-1, HGF, FGF-2), and their exosomal cargo (miR-1, miR-133a) activates endogenous muscle repair pathways. Anti-fibrotic paracrine effects (TGF-β suppression, MMP secretion) prevent replacement of contractile tissue with fibrotic scar.

Process

Mechanism of Action

Satellite Cell-Like Engraftment & Self-Renewal: Pax7+ muscle progenitors home to the satellite cell niche beneath the basal lamina of host myofibers via M-Cadherin and integrin-β1 adhesion, engaging the same niche behavior and self-renewal dynamics characterized in the adult muscle satellite cell compartment.^[2] In this niche, they undergo quiescence — the hallmark of functional satellite cells, consistent with satellite cell differentiation dynamics observed in single-fiber culture systems.^[3] Upon activation by muscle injury or exercise signals (FGF-2, HGF, NO), they proliferate and express MyoD+, then MyoG+, and fuse into host myotubes or form new myofibers. This niche-integrated engraftment is intended to provide more sustained regenerative capacity than simple myoblast injection, which the literature associates with poor long-term persistence without a self-renewing niche reservoir.

Myofiber Fusion & Fiber Hypertrophy: AB myoblasts express M-Cadherin and NCAM, enabling fusion with existing host myofibers and increasing fiber cross-sectional area and contractile force. In DMD models, transplanted myoblasts producing dystrophin contribute this critical structural protein to the dystrophin-deficient host fiber, partially correcting the molecular deficit that drives DMD fiber necrosis.

Paracrine Amplification of Host Satellite Cells: IGF-1 activates the IGF-1R/PI3K/Akt/mTOR anabolic pathway in satellite cells and myotubes — the master regulator of muscle protein synthesis and fiber hypertrophy.^[4] HGF activates the Met receptor, the primary satellite-cell-activating factor that breaks quiescence and initiates proliferation. FGF-2 drives satellite cell proliferation and prevents premature differentiation, expanding the progenitor pool before fusion. Anti-fibrotic cargo (HGF, decorin, miR-29) suppresses TGF-β-driven fibroblast activation — a mechanism established in renal^[5] and pulmonary/sarcoid^[6] fibrosis models and expected to extend to dystrophic muscle rather than a finding directly established in muscle tissue — reducing fibrotic replacement of muscle tissue.

Biomarkers

Key Biomarkers & Molecular Cargo

Marker / Molecule	Functional Role
Pax7	Satellite cell identity master TF; required for satellite cell self-renewal; marks quiescent and activated satellite cells
MyoD (MYOD1)	Myogenic determination factor; activated upon satellite cell activation; drives myogenic lineage commitment and proliferation
Myf5	Early myogenic TF expressed with Pax7 in satellite cells; required for myogenic lineage specification
Desmin	Muscle-specific intermediate filament; myoblast and myotube identity marker; structural component of sarcomere Z-disc
M-Cadherin	Satellite cell niche adhesion molecule; enables engraftment beneath basal lamina; required for myoblast fusion
Myogenin (MyoG)	Late myogenic TF expressed upon differentiation; drives terminal myoblast differentiation and fusion into myotubes
IGF-1 / HGF / FGF-2	Paracrine satellite cell activating factors — break quiescence and amplify host satellite cell regeneration
miR-1 / miR-133a	Muscle-specific miRNAs in exosomal cargo; regulate satellite cell proliferation vs. differentiation balance
Anti-fibrotic cargo	Decorin, HGF, miR-29 suppress TGF-β-driven fibrosis in dystrophic and aging muscle

Applications

Potential Applications

Duchenne Muscular Dystrophy (DMD): dystrophin-contributing myoblasts fuse with deficient host fibers; satellite cell niche replenishment; anti-fibrotic; paracrine muscle fiber protection.
Becker Muscular Dystrophy: fiber strength augmentation; partially functional dystrophin contribution.
Limb-Girdle Muscular Dystrophy: muscle progenitor replacement; paracrine fiber support.
Age-Related Sarcopenia: satellite cell pool replenishment, IGF-1-mediated mTOR activation, and anti-fibrotic paracrine signaling are each independently documented mechanisms in the sarcopenia literature.
Critical Illness Myopathy / ICU-Acquired Weakness: rapid muscle fiber regeneration; mitochondrial donation to atrophied fibers.
Myositis (Polymyositis / Dermatomyositis): combined immunomodulation (MSC-inherited) and structural muscle repair.
Sports-Related Muscle Injuries (Grade II–III tears): accelerated regeneration; reduced fibrotic scar formation; faster return-to-sport timelines. A Phase 1/2 feasibility trial of regenerative cells in Grade II hamstring tears (NCT02045888) established safety.
Sphincter Repair (Urinary / Fecal Incontinence): urethral and anal sphincter myoblast injection for sphincter regeneration.

These are experimental use cases, provided as a scientific reference for researchers. Except where noted, they did not use Akira Biotech materials, and results may not be reproducible with ours. Akira Biotech supplies laboratory reagents for research use only. Our products are NOT approved by FDA or any regulatory authority and are not for use in or on humans.

Evidence

Clinical & Preclinical Evidence

Direct clinical trial data specific to UCT-WJ-MSC-derived skeletal muscle progenitors is not yet available. The evidence base below is translational, drawing on the published myoblast/satellite-cell transplantation literature and preclinical muscle-injury models that establish the mechanisms this product is designed to leverage.

Study / Trial	N / Design	Endpoints	Key Finding
Myoblast transplantation in Duchenne muscular dystrophy	Open-label high-density intramuscular myoblast injection studies	Dystrophin+ fiber percentage, muscle strength, safety	Published high-density injection protocols report dystrophin-positive myofiber restoration and establish clinical feasibility and safety of donor myoblast fusion into dystrophin-deficient host fibers, though this specific figure is not tied to a single verifiable published source
Satellite cell transplantation in aged muscle	Aged/sarcopenic rodent models; satellite cell or myoblast transplantation	Myofiber cross-sectional area, grip strength, satellite cell pool size	Transplanted progenitors engraft in the aged satellite cell niche and support recovery of myofiber cross-sectional area and grip strength, illustrating reversal of age-related satellite cell pool decline — directionally supportive rather than quantitatively definitive
Cardiotoxin / volumetric muscle loss injury models (preclinical)	Rodent cardiotoxin injury and volumetric muscle loss (VML) models	Myofiber regeneration rate, fibrotic area, contractile force recovery	Cell-based treatment accelerates myofiber regeneration and reduces fibrotic replacement relative to untreated injury, with improved contractile force recovery
MSC-EV / muscle exosome cargo^[7]	Multiple preclinical models; systematic review	Myokine cargo, satellite cell activation, anti-atrophy signaling	IGF-1, HGF, and follistatin cargo activate satellite cells and counter muscle atrophy across preclinical muscle-wasting models, supporting the companion Muscle Exosome Matrix product

Sports medicine data from regenerative clinics using UCT-MSC preparations for muscle injuries report accelerated return-to-play timelines and reduced re-injury rates, though rigorous RCT data in muscle-specific applications remain forthcoming — the one registered feasibility trial in this space (NCT02045888, Grade II hamstring tears) established safety rather than efficacy.

Skeletal Muscle Stem Cells